CAR-T race heats up with flurry of new deals

By Zachary Brennan contact

- Last updated on GMT

Renewed interest in CAR-T therapies makes the market a hot one.
Renewed interest in CAR-T therapies makes the market a hot one.

Related tags: Bone marrow

The hype around developing new CAR-T (Chimeric Antigen Receptor transduced T) cell therapies, which can fight cancers by modifying patients’ immune cells, seemed to hit a new high this week, with two partnerships and an acquisition.

Amgen kicked off the week with a research partnership with Kite Pharma. Under the terms of the agreement, Amgen will contribute cancer targets, while Kite will contribute its proprietary CAR platform, R&D and manufacturing capabilities.

Kite, which raised about $130m with its IPO in June, will be responsible for conducting all preclinical research, and cell manufacturing and processing through Investigational New Drug (IND) filing.

With an upfront payment of $60m from Amgen, as well as funding for R&D costs through an IND filing, Kite will be eligible to receive up to $525m in milestone payments per Amgen program based on the successful completion of certain milestones, plus tiered high single- to double-digit royalties for sales and the license of Kite's intellectual property for CAR-T cell products. Amgen is eligible to receive up to $525m in milestone payments per Kite program, plus tiered single-digit sales royalties. 

Novartis and Intellia

Novartis, which has worked with the University of Pennsylvania to develop its own promising CAR-T therapy, on Wednesday, announced a partnership with Intellia, which gives Novartis exclusive rights to develop programmes focused on CAR-Ts.

Research and development activities will focus on using CRISPR (clustered regularly interspaced short palindromic repeats) ex vivo for engineering CAR-Ts and hematopoietic stem cells (HSCs).

Cardio3 Acquisition

Belgian stem cell developer Cardio3 BioSciences also joined the group racing to develop CAR-T therapies by acquiring OnCyte, the oncology division of ​Celdara Medical, for an upfront payment of $10m.

For the successful development of Oncyte’s most advanced product, CM-CS1, Celdara could receive up to $50m in milestones until market approval. Celdara will also be eligible to additional payments for other product milestones totalling up to $21m per product. In addition, Celdara will receive up to $80m in sales milestones if any products reach blockbuster status, while royalties range from 5% to 8%.

OnCyte has three CAR T-cell therapy products in development and an allogeneic T-cell platform targeting a range of cancer indications. 

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us

Products

View more

Webinars